dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Carboxylases (type: enzyme)
Target: Acetyl-CoA carboxylase 1

Ligand: clesacostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.909999847412109 pIC50
Reference (Journal): Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
Published in: J Med Chem

Ligand: compound 21 [PMID: 23981033] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8 pIC50
Reference (Journal): Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure.
Published in: J Med Chem

Ligand: CP-640186 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.389999866485596 pIC50
Reference (Journal): Structure-activity relationships for a novel series of thiazolyl phenyl ether derivatives exhibiting potent and selective acetyl-CoA carboxylase 2 inhibitory activity.
Published in: Bioorg Med Chem Lett

Ligand: CP-640186 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.28000020980835 pIC50
Reference (Journal): (4-Piperidinyl)-piperazine: a new platform for acetyl-CoA carboxylase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: firsocostat (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: no
Median affinity: 8.680000305175781 pIC50
Reference (Journal): Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.
Published in: Proc Natl Acad Sci USA

Ligand: TOFA (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.909999847412109 pIC50
Reference (Journal): Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells.
Published in: Cancer Res
Target family: Carboxylases (type: enzyme)
Target: Acetyl-CoA carboxylase 2

Ligand: A-908292 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.639999866485596 pIC50
Reference (Journal): Gene expression analysis in rats treated with experimental acetyl-coenzyme A carboxylase inhibitors suggests interactions with the peroxisome proliferator-activated receptor alpha pathway.
Published in: J Pharmacol Exp Ther

Ligand: clesacostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.599999904632568 pIC50
Reference (Journal): Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
Published in: J Med Chem

Ligand: compound 21 [PMID: 23981033] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure.
Published in: J Med Chem

Ligand: compound 2e [PMID: 31900320] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.720000267028809 pIC50
Reference (Journal): A Novel Acetyl-CoA Carboxylase 2 Selective Inhibitor Improves Whole-Body Insulin Resistance and Hyperglycemia in Diabetic Mice through Target-Dependent Pathways.
Published in: J Pharmacol Exp Ther

Ligand: CP-640186 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.210000038146973 pIC50
Reference (Journal): (4-Piperidinyl)-piperazine: a new platform for acetyl-CoA carboxylase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: CP-640186 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.420000076293945 pIC50
Reference (Journal): Structure-activity relationships for a novel series of thiazolyl phenyl ether derivatives exhibiting potent and selective acetyl-CoA carboxylase 2 inhibitory activity.
Published in: Bioorg Med Chem Lett

Ligand: firsocostat (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: no
Median affinity: 8.210000038146973 pIC50
Reference (Journal): Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.
Published in: Proc Natl Acad Sci USA

Ligand: TOFA (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.909999847412109 pIC50
Reference (Journal): Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells.
Published in: Cancer Res
Target family: Carboxylases (type: enzyme)
Target: &gamma;-Glutamyl carboxylase

Ligand: anisindione (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1957)
Primary target: yes
Median affinity:  -
Target family: Carnitine palmitoyltransferases (type: enzyme)
Target: carnitine palmitoyltransferase 1A

Ligand: etomoxir (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pIC50
Reference (Journal): Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
Published in: J Med Chem

Ligand: teglicar (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.960000038146973 pIC50
Reference (Journal): Discovery of a Long-Chain Carbamoyl Aminocarnitine Derivative, a Reversible Carnitine Palmitoyltransferase Inhibitor with Antiketotic and Antidiabetic Activity
Published in: Jourmal of Medicinal Chemistry
Target family: Carnitine palmitoyltransferases (type: enzyme)
Target: carnitine palmitoyltransferase 1B

Ligand: teglicar (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.360000133514404 pIC50
Reference (Journal): Discovery of a Long-Chain Carbamoyl Aminocarnitine Derivative, a Reversible Carnitine Palmitoyltransferase Inhibitor with Antiketotic and Antidiabetic Activity
Published in: Jourmal of Medicinal Chemistry
Target family: Carnitine palmitoyltransferases (type: enzyme)
Target: carnitine palmitoyltransferase 2

Ligand: compound 16 [PMID: 17585909] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.679999828338623 pIC50
Reference (Journal): Carnitine palmitoyltransferase 2: analysis of membrane association and complex structure with a substrate analog.
Published in: FEBS Lett

Ligand: teglicar (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.619999885559082 pIC50
Reference (Journal): The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment.
Published in: Structure
Target family: Casein kinase 1 (CK1) family (type: enzyme)
Target: casein kinase 1 alpha 1

Ligand: compound 14 [PMID: 24900428] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.349999904632568 pIC50
Reference (Journal): Structure-Based Design of Potent and Selective CK1γ Inhibitors.
Published in: ACS Med Chem Lett

Ligand: D4476 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.519999980926514 pIC50
Reference (Journal): Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.
Published in: Eur J Med Chem

Ligand: IC261 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.800000190734863 pIC50
Reference (Journal): Crystal structure of a conformation-selective casein kinase-1 inhibitor.
Published in: J Biol Chem
Target family: Casein kinase 1 (CK1) family (type: enzyme)
Target: casein kinase 1 delta

Ligand: CDK inhibitor 4.35 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.349999904632568 pIC50
Reference (Journal): 3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
Published in: J Med Chem

Ligand: compound 14 [PMID: 24900428] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.230000019073486 pIC50
Reference (Journal): Structure-Based Design of Potent and Selective CK1γ Inhibitors.
Published in: ACS Med Chem Lett

Ligand: D4476 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.519999980926514 pIC50
Reference (Journal): The selectivity of protein kinase inhibitors: a further update.
Published in: Biochem J

Ligand: IC261 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6 pIC50
Reference (Journal): Crystal structure of a conformation-selective casein kinase-1 inhibitor.
Published in: J Biol Chem

Ligand: JNJ-6204 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.210000038146973 pIC50
Reference (Journal): Structure-Based Optimization of Selective and Brain Penetrant CK1&#x3b4; Inhibitors for the Treatment of Circadian Disruptions.
Published in: ACS Med Chem Lett

Ligand: PF-4800567 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.150000095367432 pIC50
Reference (Journal): Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period.
Published in: J Pharmacol Exp Ther

Ligand: PF-670462 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pIC50
Reference (Journal): An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions.
Published in: J Pharmacol Exp Ther
Target family: Casein kinase 1 (CK1) family (type: enzyme)
Target: casein kinase 1 epsilon

Ligand: IC261 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6 pIC50
Reference (Journal): Crystal structure of a conformation-selective casein kinase-1 inhibitor.
Published in: J Biol Chem

Ligand: PF-4800567 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.489999771118164 pIC50
Reference (Journal): Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period.
Published in: J Pharmacol Exp Ther

Ligand: PF-670462 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.109999656677246 pIC50
Reference (Journal): An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions.
Published in: J Pharmacol Exp Ther

Ligand: SR-4133 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.239999771118164 pIC50
Reference (Journal): Structure-Based Development of Isoform-Selective Inhibitors of Casein Kinase 1&#x3b5; vs Casein Kinase 1&#x3b4;.
Published in: J Med Chem

Ligand: umbralisib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2021)
Primary target: no
Median affinity: 5.21999979019165 pEC50
Reference (Journal): Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.
Published in: Blood
Target family: Casein kinase 1 (CK1) family (type: enzyme)
Target: casein kinase 1 gamma 1

Ligand: compound 33 [PMID: 19364658] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
Published in: Bioorg Med Chem

Ligand: voruciclib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.960000038146973 pIC50
Reference (Journal): Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.
Published in: PLoS ONE
Target family: Casein kinase 1 (CK1) family (type: enzyme)
Target: casein kinase 1 gamma 2

Ligand: compound 14 [PMID: 24900428] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pIC50
Reference (Journal): Structure-Based Design of Potent and Selective CK1γ Inhibitors.
Published in: ACS Med Chem Lett
Target family: Casein kinase 1 (CK1) family (type: enzyme)
Target: casein kinase 1 gamma 3

Ligand: compound 14k [PMID: 21982499] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
Published in: Bioorg Med Chem Lett
Target family: Casein kinase 2 (CK2) family (type: enzyme)
Target: casein kinase 2, alpha 1 polypeptide subunit

Ligand: compound 1a [PMID: 24900749] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8 pIC50
Reference (Journal): Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo.
Published in: ACS Med Chem Lett

Ligand: compound 2c [PMID: 22115617] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.079999923706055 pKi
Reference (Journal): CK2α and CK2α' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives.
Published in: Eur J Med Chem

Ligand: silmitasertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9 pIC50
Reference (Journal): Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
Published in: J Med Chem
Target family: Casein kinase 2 (CK2) family (type: enzyme)
Target: casein kinase 2, alpha prime polypeptide subunit

Ligand: compound 2c [PMID: 22115617] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.679999828338623 pKi
Reference (Journal): CK2α and CK2α' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives.
Published in: Eur J Med Chem

Ligand: silmitasertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9 pIC50
Reference (Journal): Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
Published in: J Med Chem
Target family: CASK family (type: enzyme)
Target: calcium/calmodulin dependent serine protein kinase

Ligand: compound 26 [PMID: 34543009] (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.659999847412109 pKd
Reference (Journal): Design and Development of a Chemical Probe for Pseudokinase Ca<sup>2+</sup>/calmodulin-Dependent Ser/Thr Kinase.
Published in: J Med Chem

Ligand: compound 26 [PMID: 34543009] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.099999904632568 pIC50
Reference (Journal): Design and Development of a Chemical Probe for Pseudokinase Ca<sup>2+</sup>/calmodulin-Dependent Ser/Thr Kinase.
Published in: J Med Chem
Target family: Catecholamine turnover (type: enzyme)
Target: Catechol-O-methyltransferase

Ligand: entacapone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1999), EMA (1998)
Primary target: yes
Median affinity: 9.520000457763672 pKi
Reference (Journal): Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.
Published in: Biochemistry

Ligand: entacapone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1999), EMA (1998)
Primary target: yes
Median affinity: 8.699999809265137 pKi
Reference (Journal): Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.
Published in: Biochemistry

Ligand: opicapone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA  & UK (2016), FDA 2020
Primary target: yes
Median affinity: 9 pKi
Reference (Journal): A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT).
Published in: J Med Chem

Ligand: opicapone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA  & UK (2016), FDA 2020
Primary target: no
Median affinity: 8.819999694824219 pKi
Reference (Journal): A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT).
Published in: J Med Chem

Ligand: opicapone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA  & UK (2016), FDA 2020
Primary target: no
Median affinity: 8.819999694824219 pKi
Reference (Journal): A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT).
Published in: J Med Chem

Ligand: tolcapone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (1997), FDA (1998)
Primary target: yes
Median affinity: 9.539999961853027 pKi
Reference (Journal): Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.
Published in: Biochemistry

Ligand: tolcapone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (1997), FDA (1998)
Primary target: yes
Median affinity: 9.569999694824219 pKi
Reference (Journal): Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.
Published in: Biochemistry
Target family: Catecholamine turnover (type: enzyme)
Target: Dopamine beta-hydroxylase (dopamine beta-monooxygenase)

Ligand: nepicastat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase.
Published in: Br J Pharmacol
Target family: Catecholamine turnover (type: enzyme)
Target: L-Aromatic amino-acid decarboxylase

Ligand: 3-hydroxybenzylhydrazine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: benserazide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: no
Median affinity:  -
Reference (Journal): Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors.
Published in: PLoS ONE

Ligand: carbidopa (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1977)
Primary target: yes
Median affinity:  -

Ligand: L-α-methyldopa (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1962)
Primary target: no
Median affinity:  -
Target family: Catecholamine turnover (type: enzyme)
Target: L-Phenylalanine hydroxylase

Ligand: α-methylphenylalanine (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Alpha-methylphenylalanine, a new inducer of chronic hyperphenylalaninemia in sucling rats.
Published in: Science

Ligand: fenclonine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: sapropterin (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (2007), EMA (2008)
Primary target: yes
Median affinity: 5.400000095367432 pKi
Reference (Journal): Tetrahydrobiopterin binding to aromatic amino acid hydroxylases. Ligand recognition and specificity.
Published in: J Med Chem
Target family: Catecholamine turnover (type: enzyme)
Target: L-Tyrosine hydroxylase

Ligand: 3-chlorotyrosine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: 3-iodotyrosine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: alpha-methyltyrosine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1979)
Primary target: yes
Median affinity:  -

Ligand: α-propyldopacetamide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: methyltyrosine (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1979)
Primary target: yes
Median affinity:  -
Target family: Catecholamine turnover (type: enzyme)
Target: Phenylethanolamine N-methyltransferase

Ligand: LY134046 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.6 pKi
Reference (Journal): Properties of 8,9-dichloro-2,3,4,5-tetrahydro-1H-2-benzazepine, an inhibitor of norepinephrine N-methyltransferase.
Published in: Biochem Pharmacol